diagnosis copd
TRANSCRIPT
-
7/23/2019 Diagnosis Copd
1/12
SINTYA
1210211132
Global Strategy for Diagnosis, Management andPrevention of COPD
Combined Assessment of
COPD
-
7/23/2019 Diagnosis Copd
2/12
Global Strategy for Diagnosis, Management and Prevention of COPD
Combined Assessment of COPD
Risk
(GOLD
ClassificationofAirflow
Limitation)
Risk
(Exacerbation
history)
> 2
1
0
(C) (D)
(A) (B)
mMRC 01
C!" # 10
$
%
2
1
mMRC > 2
C!" > 10
Symptoms(mMRC or C!" score))
-
7/23/2019 Diagnosis Copd
3/12
COPD Assessment Test (CAT): An 8-item measure of health statusimpairment in COPD
http!""#atestonline$org%$
Breathlessness Measurement using the
Modifed British Medical ResearchCouncil (mMRC) Questionnaire!relates&ell to other measures of health status
and predi#ts future mortality ris'$
Global Strategy for Diagnosis, Management and Prevention ofCOPD
Assessment of Symptoms
-
7/23/2019 Diagnosis Copd
4/12
COPD Assessment (est CA(%
Measures health status
)ased on 8 *uestions
S#ore from + to
igh s#ores . symptoms May predi#t e/a#erbation
htt&'*catestonline*or+en+lishin,ex*htm
-
7/23/2019 Diagnosis Copd
5/12
Global Strategy for Diagnosis, Management and Prevention ofCOPD
Mo,ifie, MRC (mMRC)-.estionnaire
-
7/23/2019 Diagnosis Copd
6/12
Global Strategy for Diagnosis, Management and Prevention of COPD
Combined Assessment of COPD
(C) (D)
(A) (B)
mMRC 01
C!" # 10
mMRC > 2
C!" > 10
Symptoms(mMRC or C!" score))
/f mMRC 01 or C!" # 10' Less ym&toms (! or C)
/f mMRC > 2 or C!" > 10'
More ym&toms ( or D)
!ssess sym&toms first
-
7/23/2019 Diagnosis Copd
7/12
Global Strategy for Diagnosis, Management and Preventionof COPD
Classi0#ation of Severity of
Air1o& 2imitation in COPD34n patients &ith 567"57C 9 +$:+!
GO2D ! Mild 567; 8+< predi#ted
GO2D =! Moderate +< 9 5679 8+! Severe >+< 9 5679 + 2
1
0
(C) (D)
(A) (B)
mMRC 01
C!" # 10
$
%
2
1
mMRC > 2
C!" > 10
Symptoms(mMRC or C!" score))
4f GO2D or = and only+ or e/a#erbations per
year!2o& @is' A or )%
4f GO2D > or ? ort&o or
more e/a#erbations peryear!
igh @is' C or D%
!ssess ris of exacerbations next
-
7/23/2019 Diagnosis Copd
9/12
Global Strategy for Diagnosis, Management and Prevention of COPD
Combined Assessment of COPD
Risk
(GOLD
ClassificationofAirflow
Limitation)
Risk
(E
xacerbationhistor
y)
> 2
1
0
(C) (D)
(A) (B)
mMRC 01
C!" # 10
$
%
2
1
mMRC > 2
C!" > 10
Symptoms(mMRC or C!" score))
Patient is no& in one offour #ategories!
A! 2ess symptoms, lo&ris'
)! More symptoms, lo&
ris'
C! 2ess symptoms, highris'
D! More symptoms, highris'
3se combine, assessment
-
7/23/2019 Diagnosis Copd
10/12
Patient Characteristic SpirometricClassification
Exacerbationsper year
mRC CA!
!Lo Ris
Less ym&tomsGOLD 12 4 1 01 # 10
Lo Ris
More ym&toms GOLD 12 4 1 > 2 5 10
C6i+h Ris
Less ym&tomsGOLD %$ > 2 01 # 10
D6i+h Ris
More ym&tomsGOLD %$ > 2 > 2
5 10
Global Strategy for Diagnosis, Management and Preventionof COPD
Combined Assessment of
COPD
When assessing risk, choose the highestrisk
according to GOLD grade or exacerbation history
-
7/23/2019 Diagnosis Copd
11/12
Global Strategy for Diagnosis, Management and Prevention of COPD
Manage Stable COPD! Pharma#ologi# (herapy(Medications in each %o& are mentioned in al'ha%etical order and thereore notnecessaril in order o 'reerence+)
Patient "irst choice Secon# choice Alternati$e Choices
!!M! &rn
or!! &rn
7L!M!or
L!!or
!! an, !M!
"heo&hylline
7L!M!
orL!!
7L!M! an, L!!!! and/or!M!
"heo&hylline
C
7/C 8 L!!
or7L!M! 7L!M! an, L!!
79DE$inh*
!! an,or!M!"heo&hylline
D
7/C 8 L!!or
7L!M!
/C an, 7L!M! or7/C 8 L!! an, 7L!M! or
7/C8L!! an, 79DE$inh* or7L!M! an, L!! or
7L!M! an, 79DE$inh.
Carbocysteine!! an,or!M!
"heo&hylline
-
7/23/2019 Diagnosis Copd
12/12